KAIST Professor Hyun Wook Ka >KAIST announced on the 13th that a research team led by Professor Hyun Wook Ka of the Assistive AI Lab within the ...
Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI —TOKYO, March 12, 2026 ...
Tribune Online on MSN
The suspended airport cashless policy
THE decision by President Bola Tinubu last week to suspend the cashless payment system at airport toll gates across Nigeria was greeted by many travellers with relief. Since the policy took effect on ...
Vietnam Investment Review on MSN
PRISM BioLab and Receptor AI partner on drug discovery
TOKYO, March 13, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") ...
This is the first transaction of its kind for Airengy, signaling the start of ownership and operation activity of revenue-generating energy assets in Europe.” — Tal Raz, CEO of Airengy RA’ANANA, ...
Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established ...
In Lyndhurst, there’s a place where eating utensils are forbidden, grown adults scream themselves hoarse for strangers in armor, and nobody questions why there’s a castle next to the highway. Medieval ...
Abitibi Metals Corp. (CSE: AMQ) (OTCQB: AMQFF) (FSE: FW0) (“Abitibi” or the “Company”) is pleased to announce the successful completion of the second phase of its option agreement with SOQUEM Inc.
PrizePicks reports that prediction markets, which surged during the 2026 Super Bowl, differ from sports betting in pricing, ...
Iran has aimed to keep the much more powerful US military and its allies off balance through proxies in Iraq, Lebanon and ...
The challenges of connecting molecular changes to tissue structure and highlights the potential of multifractal frameworks to quantify complex biological patterns ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results